Report Preview

Plasma Fractionation Market By Product (Immunoglobulins, Coagulation Factors, Protease Inhibitors, and Albumin) By Application (Immunology, Hematology, Neurology, Oncology and Rheumatology & Orthopedics) By Method (Centrifugation, Depth Filtration, and Chromatography) By End user (Hospitals & Clinics, Clinical Research Laboratories and Academic & Research Institutes) – Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2022-2031.

In 2021, the market for Molecular Diagnostics worldwide was worth $29 billion US dollars. The market will reach US$ 39 billion by 2031, growing at a CAGR of 8.5 percent between 2022 and 2031.

Market Dynamics

The increasing prevalence of chronic diseases across all age groups, the growing use of immunoglobulins in various therapeutic areas, and the expansion of plasma collection centers drives the market growth. The increasing incidences of blood and respiratory diseases is expected to enhance the opportunities for market growth.

The rising demand for Plasma Derived Medicinal Products Drives the Market Growth Plasma-derived Medicinal Products (PDMPs) are prepared industrially with the help of human plasma. These products include immunoglobulins, albumin, and coagulation factors. The World Health Organization included several PDMP products in the list of essential medicines. This initiative highlighted these medications to be effective & safe for major needs in a healthcare system. The strong requirement for plasma derived products increases the demand for plasma procedures, leading to positive market growth. However, the emergence Recombinant Therapies are used as an alternative to Plasma Derived Medicines restring the market growth. In recent years, many different recombinant alternatives have been developed for different plasma driven therapies. Recombinant products are used prophylactically & are comparatively less immunogenic than plasma derived products.

COVID Impact

The plasma fractionation market has shown a positive impact during the COVID-19 pandemic period. The recent treatments for COVID-19 caused by the novel coronavirus SARS-CoV-2 has been largely restricted to general supportive cares with the provision of critical care as no other approved therapies are available. Many countries are preferring plasma therapy in the treatment of COVID-19. Recovery plasma treatment involves, injecting the patient with the convalescent serum of patients who have recently recovered from the COVID-19 infection. The serum of COVID-19-cured individuals has virus-neutralizing antibodies that can help as a passive antibody therapy to the infected patient. It is known as the convalescent sera of COVID-19. These convalescent sera are being collected by two ways (i) using an apheresis machine/cell separator machine and (ii) using blood withdrawal followed by centrifuge technique. As plasma treatment had positive effects on patients, various initiatives are taken by companies and government organizations to expand the use of plasma therapy during the COVID-19 pandemic.

Regional Trend

Geographically, the global plasma fractionation market is segmented into North America, Latin America, Asia Pacific, Europe, and Middle East & Africa. North America is dominating the largest share of the global plasma fractionation market with a share of 53.93% in 2021. Moreover, Asia Pacific is lined up to register the highest CAGR during the forecast period. The growth in the market in Asia-Pacific is driven by collaborations and partnerships between the countries for establishing plasma fractionation facilities. Growing awareness programs for an increase in the use of plasma and its significant. The rise in different medical conditions, such as the rising prevalence of hemophilia among countries such as China & India that require the use of plasma fractionation products. Also the increasing geriatric population in the Asia Pacific region contributes to the market growth.

Competitive Landscape

Key players operating in the global tissue diagnostics market are ADMA Biologics, Inc., Bharat Serum and Vaccine Ltd., Bio Products Laboratory Ltd., Biopharma Labs, Biotest AG, Centurion Pharma, China Biologic Products Holdings, Inc., CSL Limited, Fusion Healthcare, GC Biopharma Corp., Grifols S.A., Intas Pharmaceuticals Ltd., Kamada Pharmaceuticals, Kedrion S.p.A., LFB S.A., Octapharma AG, Plasmagen Bioscience Pvt. Ltd., Sanquin, Sichuan Yuanda Shuyang Pharmaceutical Co. Ltd., SK Plasma, Takeda Pharmaceutical Company Limited, and Virchow Biotech Ltd. among others. In April 2020, Octapharma AG launched a special project team to new therapies for COVID-19. The company also partnered with other leaders in plasma fractionation to develop a potential plasma derived hyper-immune immunoglobulin therapy for treatment of COVID-19.

Key USP’s-

According to WHO, in March 2021, the WHO Model List of essential medicines includes several plasma derivate medicinal products (PDMPs), identifying them as drugs thought to be the most efficient & secure for addressing the most essential requirements in a health system & providing guidelines on growing supply of PDMPs in low & middle income countries.

Market Segmentation

Based upon the Product used in Plasma Fractionation Market is segmented into four segments of Immunoglobulins, Coagulation Factors, Protease Inhibitors and Albumin in the fractionation process. Further it is categorized according to its process and utilization. Based on application, the Plasma Fractionation Market is segmented into Immunology, Oncology, Hematology, Neurology and Rheumatology & Orthopedics. Based on Methods, the Plasma Fractionation Market is segmented into Centrifugation, Depth Filtration, and Chromatography. In this segments, the neurology segment is expected to dominate the largest share of the plasma fractionation market. The large market share of this segment is attributed to factors such as the increasing prevalence of neurological disorders & the wide use of plasma derived products for their treatment.

End user segment of plasma fractionation market is further classified into Hospitals & Clinics, Clinical Research Laboratories and Academic & Research Institutes. The hospitals and clinics segment is expected to dominate for the largest share of the plasma fractionation market. The growing use of plasma based products in multiple therapies, the rising number of hospitals, and the increasing healthcare expenditure are some of the major factors driving the growth of this segment.

By Product

• Immunoglobulins

• • Intravenous Immunoglobulins (IVIg)
  • Subcutaneous Immunoglobulins (SCIg)
  • Intramuscular Immunoglobulins (IMIg)

• Coagulation Factors
• Protease Inhibitors
• Albumin

By Application

• Immunology
• Hematology
• Oncology
• Rheumatology & Orthopedics
• Neurology

 By Method

• Centrifugation
• Depth Filtration
• Chromatography

By End User

• Hospitals & Clinics
• Clinical Research Laboratories
• Academic & Research Institutes